Pre-earnings brief
Reports
Wed, Nov 4, 2026
Est. EPS
—
Est. revenue
—
Implied move
±17.0%
EPS beat rate
50%
Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing treatments for various disorders related to cortisol, a stress hormone. With a market cap of $13 billion, the company plays a significant role in the healthcare sector, particularly in addressing conditions like Cushing's syndrome and major depressive disorder.
Last quarter
In Q2 2026, Corcept reported an EPS of $0.36, significantly beating expectations of a loss. However, the stock fell by 1.32% the following day, indicating mixed investor reactions.
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
+124.66%
Avg 1-day reaction
-0.49%
Overall, investors are cautious ahead of the earnings report, especially given the mixed results from previous quarters. The market is likely looking for clarity on revenue growth and treatment sales.
Bull case
If Corcept can demonstrate strong revenue growth and continued profitability, it could lead to positive investor sentiment and a potential stock price increase.
Bear case
Conversely, if the company fails to meet expectations for revenue or shows signs of declining treatment sales, it could lead to a significant drop in stock price.
The print will turn on these.
Q1
What are the sales figures for cortisol treatments this quarter?
Sales figures will be crucial in assessing the company's market performance and growth potential.
Q2
How does management view the competitive landscape for cortisol-related therapies?
Understanding the competitive landscape will provide insights into potential challenges and opportunities for Corcept.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating Corcept's potential for revenue growth, particularly in the cortisol treatment market, where demand remains strong.
Supporting evidence
The company's recent EPS surprise indicates stronger-than-expected profitability, which may not be fully reflected in current stock prices.
The options market is pricing in a significant move, suggesting that investors expect volatility, which could indicate underlying strength.
Key risk
If treatment sales exceed expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around Corcept's ability to sustain growth in a competitive pharmaceutical market.
Bull confirmed if
Demonstrating revenue growth of over 15% year-over-year would confirm the bull case.
Bear confirmed if
A decline in treatment sales or revenue below expectations would confirm the bear case.
What the market is pricing for the move.
Implied Move
±16.52%
Historical Avg
±2.6%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±17.0% while CORT has averaged ±2.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
37.3%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.7%, with a raw directional average of -0.1% (roughly flat historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$5.0M
43,333 sh
3 insiders
Net
$5.0M
Net selling
Most Active Insiders· 9 open-market trades
$2.9M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
76.91%
of float
Insider
11.45%
of float
Holders
545
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
12,432,023 sh · $1.5B
11.50%
2.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Corcept beats expectations, history suggests the stock could rise by around 2.57% on the first day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may remain relatively stable, reflecting cautious investor sentiment.
Miss
A miss could lead to a decline of approximately 0.61%, as seen in past quarters when expectations were not met.
The lines on the call that would change the story.
$1.2M
Net selling
$967,447.91
Net selling
Recent Transactions
Oct 2, 2026 · @ $116.12
15,843 sh
$1.8M
Oct 2, 2026 · @ $116.55
8,744 sh
$1.0M
Oct 2, 2026 · @ $116.58
5,147 sh
$600,063.00
Oct 2, 2026 · @ $116.54
4,744 sh
$552,869.08
Oct 2, 2026 · @ $115.70
4,446 sh
$514,388.86
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Ingalls & Snyder LLC
7,934,507 sh · $949.0M
7.34%
4.3%
Renaissance Technologies, LLC
5,261,628 sh · $629.3M
4.87%
-7.4%
Vanguard Portfolio Management LLC
5,044,638 sh · $603.3M
4.67%
4.7%
Vanguard Capital Management LLC
4,172,482 sh · $499.0M
3.86%
2.3%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.